
Deerfield wins sweetened bid to acquire NitroMed
Executive Summary
After upping the ante twice, investment firm Deerfield Management has won its latest bid to acquire nitric oxide therapeutics biotech NitroMed for $0.80 in cash for each outstanding share--60% higher than its original offer--or about $36.8mm (over twice NitroMed's 2007 sales).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com